Painful Week for Individual Investors Invested in Exscientia Plc (NASDAQ:EXAI) After 12% Drop, Institutions Also Suffered Losses

Key Insights The considerable ownership by individual investors in Exscientia indicates that they collectively have a greater say in management and business strategy A total of 6 investors have a ma

Simply Wall StJun 11 09:50 ET

Germany's Merck Bets on AI Drug-Design Partnerships, Rules Out Acquisitions - Interview

By Helena Smolak and Stefanie Haxel Germany's Merck KGaA is betting on artificial-intelligence partnerships to develop new drugs, but refraining from bringing in external expertise through acquisitio

WSJJun 7 07:55 ET

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

— AI drug design pioneer John P. Overington, Ph.D., appointed to Chief Technology Officer to maximise strategic technology integration and application — — Maria-Louise Fjällskog, M.D., Ph.D., appointed interim Chief

BusinesswireJun 6 07:00 ET

Can Exscientia (EXAI) Climb 57.17% to Reach the Level Wall Street Analysts Expect?

Yahoo FinanceJun 3 09:55 ET

Exscientia to Present at Upcoming Investor Conferences in June

Exscientia plc (NASDAQ:EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in June: Barclays Digital and Disruptive Technology Conference. Panel

BusinesswireMay 30 07:00 ET

Analysts Are Upgrading Exscientia Plc (NASDAQ:EXAI) After Its Latest Results

Yahoo FinanceMay 25 08:11 ET